This CME-certified enduring activity is jointly provided by Rutgers Biomedical and Health Sciences and RedMedEd.
Support for this activity has been provided through an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Severe, treatment-resistant asthma continues to be an extreme clinical challenge. An estimated 3%–10% of asthma patients have severe asthma, which is characterized by persistent symptoms, compromised lung function, and a significantly increased frequency and severity of high-risk outcomes.
Fortunately, there have been important developments regarding the clinical management of patients with severe asthma. The discovery that severe asthma comprises multiple phenotypes and distinct endotypes linked to differences in airway remodeling and inflammatory pathophysiology has potentially significant implications for managing this patient population. Also, several new tailored biologic therapies have been approved by the US Food and Drug Administration for use in patients with treatment-resistant severe asthma driven by eosinophilic inflammation, with other new treatments in late-stage development. In 2019, the Global Initiative for Asthma (GINA) updated its stepwise treatment guidelines; these guidelines address the use of biologic therapy for patients with severe asthma.
In this edition of RME Hot Seat, the members of our expert faculty answer challenging clinical questions on existing and emerging personalized treatment, strategies for implementing the most recent clinical guidelines when choosing optimal treatments for patients with severe asthma, the use of biomarkers to guide diagnosis and therapy, differentiating between severe asthma and poorly controlled asthma, and more.
This activity has been designed to meet the educational needs of allergists, immunologists, pulmonologists, and primary care providers (including nurse practitioners and physician assistants) involved in the care of patients with severe asthma.
Upon completion of this activity, participants should be better able to discuss the most recent clinical guidelines for severe asthma treatment.
To help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, Rutgers Biomedical and Health Sciences has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by Sugeet Jagpal, MD, Assistant Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
This activity was pilot-tested for time required for participation by Ibrahim El Husseini, MD, and Renuka Rajagopal, MD.
Conflict Of Interest Disclosure Policy
According to the disclosure policy of Rutgers Biomedical and Health Sciences and to conform with Joint Accreditation requirements and FDA guidelines, individuals who are in a position to control the content of this educational activity are required to disclose to activity participants the existence of any relevant relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exception of nonprofit or government organizations and non–health care related companies, within the past 12 months. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
Michael E. Wechsler, MD, MMSc—Program Chair Professor of Medicine Director, Cohen Family Asthma Institute National Jewish Health Denver, Colorado
Dr. Wechsler has disclosed the following relevant financial relationships: Grant/Research Support: AstraZeneca, GlaxoSmithKline, Novartis Pharmaceuticals, Sanofi, Teva Pharmaceuticals USA Consultant: AstraZeneca, Equillium, Gala Therapeutics, Genentech, Genzyme, GlaxoSmithKline, Novartis Pharmaceuticals, Pulmatrix, Regeneron Pharmaceuticals, resTORbio, Sanofi, Sentien Biotechnologies, Teva Pharmaceuticals USA
Bradley E. Chipps, MD Medical Director Capital Allergy & Respiratory Disease Center Sacramento, California
Dr. Chipps has disclosed the following relevant financial relationships: Consultant, Speakers Bureau and Scientific Advisory Board: AstraZeneca, Circassia Pharmaceuticals, Genentech, Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Teva Pharmaceuticals USA
Flavia C. Hoyte, MD Associate Professor of Medicine Allergy/Immunology Fellowship Training Program Division of Allergy/Immunology National Jewish Health University of Colorado Denver, Colorado
Dr. Hoyte has disclosed the following relevant financial relationships: Grant/Research Support: AstraZeneca, GlaxoSmithKline, Novartis Pharmaceuticals, Teva Pharmaceuticals USA
Accredited Provider Disclosures
Reviewer Sugeet Jagpal, MD, has disclosed no relevant financial relationships.
Field Testers Ibrahim El Husseini, MD, and Renuka Rajagopal, MD, have disclosed no relevant financial relationships.
Rutgers Biomedical and Health Sciences Center for Continuing and Outreach Education Patrick Dwyer, Director, CME, has disclosed no relevant financial relationships.
RedMedEd Denise LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships. Yvette Murley, PhD, Medical Director, has disclosed no relevant financial relationships. Heather Rafa, Program Manager, has disclosed no relevant financial relationships. Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships. Karen Smith, Creative Director, has disclosed no relevant financial relationships.
AMA PRA Category 1 Credit(s)TM
In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and RedMedEd. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabled Use
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Dr. Wechsler discusses the investigational use of nonapproved products, including CRTH2 antagonists, anti-TSLP, and anti-IL33. Rutgers Biomedical and Health Sciences and RedMedEd do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any manufacturer of pharmaceuticals or devices, Rutgers Biomedical and Health Sciences or RedMedEd. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Clicking "START ACTIVITY" will send you away from myCME to our partner site, RedMedEd, to complete the activity.
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 80% or greater) and program evaluation. Certificates can be printed immediately and will not be stored in your myCME CME History.
For questions regarding CME credit, please contact Rutgers Biomedical and Health Sciences at 973-972-4267 or email@example.com.
For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or firstname.lastname@example.org.